April 15, 2026

Is Standard of Care Optimal for the Individual Patient?

I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded ...

The ASCO Post

April 09, 2026

Japanese Study Looks at Rates of Cancer Therapy–Related AML

A population-based study in Japan has revealed a gradual increase in the rates of therapy-related acute myeloid leukemia (AML) in recent years—especially after breast cancer treatment. 

The ASCO Post

April 08, 2026

Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis

Results from a small phase II study suggest that a triplet regimen may improve symptoms and extend survival in some patients with breast cancer and leptomeningeal metastasis, who often face limited tr...

The ASCO Post

April 03, 2026

HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patien...

The ASCO Post

April 01, 2026

Early Results From a Trial of Active Surveillance for Low-Risk DCIS are ‘Reassuring,’ Say Researchers

“For women with low-risk DCIS, these interim results are reassuring. There is currently no indication that active surveillance leads to worse early outcomes compared with immediate surgery. It’s impor...

The ASCO Post

March 30, 2026

Radiotherapy May Reduce Risk of Lymphedema in Patients With Breast Cancer More Effectively Than Surgery

These results come from the pilot phase of the phase III ADARNAT randomized international clinical trial, which is investigating whether axillary radiotherapy has a lower risk of lymphedema than axill...

The ASCO Post

March 30, 2026

Breast Cancer Recurrence Remains Low—Even After 10 Years—With Radiotherapy Tailored to Patient’s Individual Risk

“The results of our study show that tailoring the extent of radiotherapy according to how well the chemotherapy has worked to treat cancer in the lymph nodes leads to very low and reassuring recurrenc...

The ASCO Post

March 30, 2026

Breast Reconstruction Using Polyurethane-Coated Implants May Reduce the Risk of Capsular Contracture, Additional Surgery

Women who are treated with mastectomy for breast cancer often choose to have surgery to reconstruct the breast using an implant. But hard, painful scar tissue can form around the implant, especially w...

The ASCO Post

January 29, 2026

Addition of CDK 4/6 inhibitor benefits patients with HR+, HER2+ metastatic breast cancer, new study shows

The addition of a CDK 4/6 inhibitor to standard therapy in patients with “double-positive” metastatic breast cancer significantly extended the time the disease did not progress according to data published today in the New England Journal of Medicine.

Dana-Farber

March 10, 2023

Four Leading UPMC/Pitt Scientists Receive Funding for Research in Breast Cancer

UMPC Hillman Cancer Center researchers receive significant funding from the Breast Cancer Research Foundation to support investigations aiming to improve cancer screening and enhance HER2 therapy.

The ASCO Post